What is ALS Phase 3 Study TRO19622?
CATEGORY:
NCT01285583 is an open-label safety extension study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole. The drug TRO19622 is also known as olesoxime. Other study names are TRO19622 CL E Q 1425-1.
Save up to 80% off your prescriptions!
How do members experience ALS Phase 3 Study TRO19622?
Top 5 reported purposes & perceived effectiveness
Purpose | Patients | Evaluations | Perceived Effectiveness |
---|---|---|---|
Participate in clinical trial | 3 | 3 |
Side effect severity
Severity | Evaluations | Percentage |
---|---|---|
Severe | 0 | |
Moderate | 0 | |
Mild | 0 | |
None | 4 |
Member evaluations
Madryn
evaluated on Dec 28, 2011
- Perceived effectiveness for Participate in clinical trial: None
- Side effects: None
cinéphile 94
evaluated on Dec 14, 2011
- Perceived effectiveness for Participate in clinical trial: None
- Side effects: None
Learn more about our community’s experience with ALS Phase 3 Study TRO19622
What are people saying about ALS Phase 3 Study TRO19622?
5
5
members have reported taking ALS Phase 3 Study TRO19622
Join the conversation and connect with people who have taken ALS Phase 3 Study TRO19622
Last updated: